Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation and orphan-drug designation from the US Food and Drug Administration (FDA) for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of drug refractory paroxysmal Atrial Fibrillation (AFib).

Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently

Plus Therapeutics, Inc. a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx, a leading radiopharmaceutical contract developer and manufacture

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as 1 year of age. Specifically, the approval covers children

Duoning Biotechnology Group announced a strategic partnership agreement with Branca Bunús Ltd. ("Branca Bunús"). Under this agreement, the two companies will collaborate on the development, optimization, and application of transfection reagents

PHAXIAM Therapeutics a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announces that it has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its Phase II study,

Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced new strategic partnerships with the Agency for Science, Technology, and Research

Olon, a pharmaceutical manufacturer and global CDMO company, confirms the timeline for the construction of its new high potency API manufacturing facility in Rodano (Milan) and confirms that the installation and validation of the new small-scale production area within the facility has already been successfully completed.

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies.